However, in the COMBAT trial, the synergistic treatment of metastatic PDAC with the CXCR4 antagonist BL8040 and pembrolizumab increased tumor-infiltrating CD8+ effector T lymphocytes, reduced the density of MDSCs in tumors, and reduced the number of circulating Tregs 149. This evidence concerns the gene CXCR4 and neoplasm.